Clinical trials: Antibody-mediated Rejection
Lung Transplantation, Antibody Mediated Rejection
Quantitative Parameters of HLA-DQ Antibodies in Lung Transplantation
The aim is to compare the quantitative parameters of de novo anti-HLA DQ Donor Specific Antibodies (DSA), determined at the time of their discovery by surface plasmon resonance (SPR), between recipients that developed a Chronic…
- Conditions
- Lung Transplantation, Antibody Mediated Rejection, Chronic Lung Allograft Dysfunction
- Trial name
- AFFIHLA-P (NCT03474536)
- Where
- 5 sites in France
- Volunteers
- 88 people
- Sponsor
- University Hospital, Bordeaux
Chronic Antibody-mediated Rejection (cABMR)
Allogeneic Umbilical Cord Mesenchymal Stromal Cells for the Treatment of Chronic Antibody-Mediated Rejection in Kidney Transplantation
Kidney transplantation is the best treatment for end-stage chronic kidney disease (CKD), improving survival and quality of life, while reducing treatment costs.
- Trial name
- SCARR (NCT06886646)
- Testing
- Allogeneic Mesenchymal Stromal Cell Therapy
- Where
- France
- Volunteers
- 22 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Antibody-mediated Rejection, NMO Spectrum Disorder
Biorepository and Registry for Plasma Exchange Patients
Patients who have immune mediated diseases commonly undergo plasma exchange (PLEX) procedures to remove pathological substances, typically believed to be antibodies.
- Conditions
- Antibody-mediated Rejection, NMO Spectrum Disorder, TTP, CIDP
- Trial name
- NCT05004493
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Charles M Knudson
ABO Blood Type Incompatible Kidney Transplantation, Antibody-mediated Rejection
Diagnostic Efficacy of Molecular Diagnostic Method for AMR in ABOiKT
The purpose of this study is to determine whether the peripheral blood marker-based molecular diagnostic method developed in the previous study can differentiate and predict accommodation and antibody-mediated rejection (AMR) in…
- Trial name
- NCT04541914
- Testing
- 5-gene classification model
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Seoul National University Hospital
Antibody-mediated Rejection, Kidney Transplant; Complications
Clazakizumab for Chronic and Active Antibody Mediated Rejection Post-Kidney Transplant
Antibody mediated rejection (ABMR) is a unique, significant and often severe form of allograft rejection. This single center, phase I/II, open label single-arm exploratory study focuses on enrolling ten patients with biopsy…
- Conditions
- Antibody-mediated Rejection, Kidney Transplant; Complications, Transplant Glomerulopathy, Transplant Glomerulopathy - Late Form
- Trial name
- NCT03380377
- Testing
- Clazakizumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Stanley Jordan, MD
Kidney Transplant Rejection, Antibody-mediated Rejection
Transplant Antibody-Mediated Rejection: Guiding Effective Treatments
This trial evaluates the addition of rituximab to standard of care in the treatment of antibody-mediated rejection in kidney transplant patients. The trial will involve adults and children.
- Trial name
- TAR:GET-1 (NCT03994783)
- Testing
- Rituximab, Methylprednisolone, Intravenous Immunoglobulin
- Where
- United Kingdom
- Volunteers
- 3 people
- Sponsor
- Imperial College London
Antibody-mediated Rejection, Allosensitization
Isatuximab in Lung Transplant Recipients
The purpose of this study is to determine the safety and feasibility of adding isatuximab to standard of care therapies in patients who will receive a lung transplant, but have significant antibodies against the donor…
- Trial name
- NCT05862766
- Testing
- Isatuximab, bone marrow biopsy
- Where
- United States
- Sponsor
- NYU Langone Health
Posttransplant Diabetes Mellitus, Acute Graft Rejection
Silymarin's Advantage on Graft Effectiveness
The study examines the impact of silymarin supplementation during the early post-transplant period, administering 900 g daily for 30 days under standard treatment.
- Conditions
- Posttransplant Diabetes Mellitus, Acute Graft Rejection, Biopsy Proven Acute Rejection, Antibody Mediated Rejection of Kidney Transplant
- Trial name
- SAGE (NCT06801886)
- Testing
- Silymarine supplementation
- Where
- Slovakia
- Volunteers
- 130 people
- Sponsor
- University Hospital, Martin
Kidney Failure, Chronic, End-Stage Renal Disease
Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant
Patients who have had a previous allograft failure represent a major problem for transplant centers as they are highly-human leukocyte antigen (HLA) sensitized and unlikely to receive another transplant without significant…
- Conditions
- Kidney Failure, Chronic, End-Stage Renal Disease, Transplant Glomerulopathy, Transplant;Failure,Kidney
- Trial name
- NCT03380962
- Testing
- Clazakizumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Stanley Jordan, MD
Kidney Transplant Rejection, Antibody-mediated Rejection
Donor-derived Cell-free DNA for Early Diagnosis of Antibody-mediated Rejection
Patients after kidney transplantation who develop donor-specific antibodies (DSA) are at high risk for antibody-mediated rejection (ABMR).
- Conditions
- Kidney Transplant Rejection, Antibody-mediated Rejection, Kidney Transplant Failure
- Trial name
- cfDNA-DSA (NCT04897438)
- Testing
- Kidney allograft biopsy depending on donor-derived cell-free DNA levels
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Charite University, Berlin, Germany
Antibody-mediated Rejection, Lung Transplant Rejection
A Prospective Randomized Trial of ECP in Subclinical AMR
The goal of this clinical trial is to evaluate the therapeutic effect of extracorporeal photopheresis in subclinical antibody-mediated rejection after lung transplantation.The main questions it aims to answer are: 1.
- Trial name
- EUROEXPORT-DSA (NCT06112951)
- Testing
- Extracorporeal Photopheresis
- Where
- 7 sites in Austria, Belgium and 5 more
- Volunteers
- 80 people
- Sponsor
- Medical University of Vienna
Antibody-mediated Rejection
Felzartamab in Late Antibody-Mediated Rejection
This prospective trial will assess the safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamics and efficacy of the fully human CD38 monoclonal antibody felzartamab in kidney transplant recipients with late active…
- Trial name
- NCT05021484
- Testing
- Felzartamab
- Where
- 2 sites in Austria, Germany
- Volunteers
- 22 people
- Sponsor
- Farsad Eskandary
Allosensitization, Kidney Transplant Rejection
Desensitization in Kidney Allograft Using Daratumumab
Patients highly allosensitized against HLA antigen awaiting for a kidney transplant have less compatible transplants to them, increasing their waitlist time and mortality.
- Conditions
- Allosensitization, Kidney Transplant Rejection, Antibody-mediated Rejection
- Trial name
- DARDAR (NCT04204980)
- Testing
- Daratumumab dose escalation, Daratumumab full dose
- Where
- France
- Volunteers
- 21 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Antibody-mediated Rejection, Kidney Tranplant
The Safety and Efficacy of CD38 Monoclonal Antibody Monotherapy for CaAMR in Renal Transplantation
Renal transplantation is the best choice for the treatment of end-stage renal disease, but the long-term survival of the graft is still remains a challenge.
- Trial name
- NCT05913596
- Testing
- Daratumumab
- Where
- China
- Volunteers
- 15 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Antibody-mediated Rejection, Kidney Transplantation
Incidence, Course and Outcome of ABMR in Kidney Transplantation
Rationale: Despite improved patient and graft survival in renal transplant recipients, still 20% of the patients reaches end-stage renal disease within 5 years after transplantation.
- Conditions
- Antibody-mediated Rejection, Kidney Transplantation, Immunosuppression
- Trial name
- PROCARE2 (NCT05140018)
- Testing
- Kidney Transplantation, Immunosuppression, Nephrectomy (kidney donation)
- Where
- 6 sites in Netherlands
- Volunteers
- 225 people
- Sponsor
- University Medical Center Groningen
Antibody-mediated Rejection in Kidney Transplant
Assess Burden of Disease Among Kidney Transplant Recipients With Chronic Active Antibody Mediated Rejection
This study investigates the burden of disease among kidney transplant recipients that have developed Chronic Active Antibody Mediated Rejection (caAMR) compared with kidney transplant recipients that have not developed caAMR
- Trial name
- NCT05452317
- Testing
- Chronic active AMR group, Non-Chronic active AMR group
- Where
- 3 sites in United States
- Volunteers
- 52 people
- Sponsor
- CSL Behring
Antibody-mediated Rejection
Subclass of Donor-specific Antibody as a Risk Factor of Antibody Mediated Rejection in Renal Transplantation
Antibody-mediated rejection is now recognized as the first cause of long-term kidney transplant loss. This type of rejection is mediated by the presence of graft-specific antibodies, usually directed against HLA (Human Leukocyte…
- Trial name
- COR-HUM (NCT04026087)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Montpellier
Lung Transplant Rejection, Antibody-mediated Rejection
Belatacept Pilot Study in Lung Transplantation Immunosuppression in Lung Transplantation
This is a pilot randomized controlled trial examining the feasibility of conducting a large scale randomized controlled trial of belatacept-based immunosuppression in lung transplantation.
- Trial name
- NCT03388008
- Testing
- Belatacept, Tacrolimus, ATG
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- Washington University School of Medicine
Decreased Immunologic Activity, Antibody-mediated Rejection
Combined Apheresis for ABO-incompatible Transplantation - a Pilot Study
Recipient desensitization is a prerequisite for successful ABO-incompatible kidney transplantation (ABOi-KTX). Published desensitization protocols commonly include the use of plasmapheresis or selective (i.e.
- Trial name
- NCT02120482
- Testing
- Combined apheresis
- Where
- Austria
- Volunteers
- 4 people
- Sponsor
- Medical University of Vienna
Antibody-mediated Rejection
Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant Recipients
This is a double-blind, randomized-withdrawal, placebo-controlled study in kidney transplant patients with AMR to evaluate the efficacy and safety of human plasma-derived C1-esterase inhibitor as add-on to standard of care (IVIG).
- Trial name
- NCT03221842
- Testing
- C1-esterase inhibitor
- Where
- 26 sites in United States, Belgium and 5 more
- Volunteers
- 63 people
- Sponsor
- CSL Behring